Groundbreaking Study Shows HPV Vaccine’s Impact on Cervical Cancer

A groundbreaking study reveals that the HPV vaccine has eliminated cervical cancer deaths in young women in England, saving around 200 lives so far.

The human papillomavirus (HPV) vaccine, introduced in England in 2008, has achieved a remarkable milestone. A recent analysis published in the Lancet shows that the vaccine has saved approximately 200 lives and eliminated cervical cancer deaths in women aged 20 to 24 between 2026 and 2026.

This groundbreaking study, led by Professor Peter Sasieni at Queen Mary University of London, highlights the vaccine’s effectiveness in preventing cervical cancer. The findings indicate that those vaccinated at ages 12 or 13 now have nearly zero risk of dying from the disease before the age of 30.

Significant Reduction in Cervical Cancer Deaths

Before the HPV vaccination campaign, around 20 deaths per year were recorded in women aged 20 to 24. The study found that without vaccination, approximately 23 deaths would have been expected in this age group between 2026 and 2026.

The elimination of these deaths marks a significant achievement in public health.

Cervical cancer remains the 14th most common cancer among females in the UK, with 3,300 people diagnosed annually. HPV, a virus spread through close skin-to-skin contact, is responsible for 99% of these cases. While most HPV infections clear up without issues, some can cause abnormal cell changes leading to cancer years later.

The Impact of HPV Vaccination

The study’s authors anticipate that the number of cervical cancer deaths will continue to decline as more individuals receive the HPV vaccine and the vaccinated population ages. Cancer Research UK, which funded the research, described the findings as an “incredible milestone” but emphasized the need to improve vaccination rates.

“We know the HPV vaccine is extremely effective at stopping cervical cancer before it starts, and for the first time, these findings show it is saving lives,” said Michelle Mitchell, chief executive of Cancer Research UK. However, vaccination rates in England are currently below the recommended levels, with only 76% of girls vaccinated by the age of 15 in 2026-25, compared to the World Health Organization’s target of 90%.

A Personal Story: Alexandra Legg’s Experience

Alexandra Legg, who left school just before the HPV vaccine was introduced, was diagnosed with cervical cancer at the age of 30 in 2026. Her diagnosis came just as she was planning her wedding. “I remember hearing the words and I just couldn’t really breathe very well,” she recalls. “I was so upset—everything went through my head; it was so hard.”

Alexandra’s treatment involved the removal of lymph nodes in her abdomen, but surgeons were able to preserve a small part of her cervix, giving her a chance to become pregnant. A year later, she gave birth to her daughter Ivy, whose middle name, Marvella, means “miracle.” “Those nine months were so scary because I was at such risk of losing her at any point,” Alexandra says.

Alexandra is now a strong advocate for the HPV vaccine. “I’m a real advocate for this vaccine, and when Ivy is old enough, she’ll be first in the queue,” she adds. Her experience underscores the importance of the vaccine in preventing cervical cancer and the potential trauma it can avert.

Future Prospects and Government Initiatives

Professor Sasieni describes the reduction in deaths as the “tip of the iceberg,” suggesting that as vaccinated generations grow older, many more lives will be saved from cervical cancer. The UK government has pledged to eliminate cervical cancer as a public health problem by 2040.

To boost vaccination rates, the Department of Health and Social Care in England is implementing various initiatives. These include rolling out catch-up HPV vaccination campaigns via community pharmacies and sending out HPV self-testing kits to women who have not yet come forward for screening. Boys have also been given the HPV vaccine since 2019, which helps protect them against anal, penis, throat, and mouth cancers and reduces the risk of passing the virus on to girls.

Despite these efforts, women aged 25 to 64 are still advised to attend cervical screening, formerly known as a smear test. The continued emphasis on screening and vaccination highlights the comprehensive approach needed to combat cervical cancer effectively.